Interleukin (IL)-4 and IL-13 are two structurally and functionally related cytokines that have overlapping but also distinct biological activities. One of the components of the IL-13 receptor, the a2 chain (IL-13Ra2), has been reported to downregulate the cell responsiveness to IL-13, without affecting IL-4 signaling. Here, we report that TNFa synergizes with either IL-4 or IL-13 in inducing the IL-13Ra2 chain at both the mRNA and protein levels in the HaCaT human keratinocyte cell line. Further studies by 5 0 RACE identified as yet undescribed exonic sequences of the IL-13Ra2 5 0 UTR, provided evidence for the expression of alternatively spliced IL-13Ra2 transcripts and defined the transcription start of the IL-13Ra2 gene. A 1.5 kb region upstream of the first exon of the IL-13Ra2 gene displayed basal promoter activity when inserted in a reporter plasmid and transiently transfected in HaCaT cells. This promoter activity was further increased in response to IL-4 and IL-13. Furthermore, by electrophoretic mobility shift assay and site-directed mutagenesis, we showed that the IL-4/IL-13-induced promoter activity depended upon a positively acting STAT6 response element. Finally, TNFa was shown to potentiate IL-4/IL-13-induced IL-13Ra2 promoter activity when the same reporter construct was studied in stably but not in transiently transfected cells. These results suggest that the synergistic effect of TNFa on IL-4/IL-13-induced IL-13Ra2 expression is dependent upon chromatin re-modeling events.
Introduction
The cytokines interleukin (IL)-4 and IL-13 are produced mainly by Th2 lymphocytes, mast cells, and basophils, and play an important role in Th2 inflammatory reactions. In particular, these cytokines are involved in the pathogenesis of atopic diseases, such as asthma and atopic dermatitis. IL-4 and IL-13 have pleiotropic and overlapping immunoregulatory activities. Indeed, IL-4 and IL-13 increase B-cell proliferation and promote IgE isotype switching (Rousset et al., 1991; Defrance et al., 1994) . IL-4 and IL-13 also increase expression of B7-1 (CD80), B7-2 (CD86) and MHC class II on B cells, thus enhancing the antigen-presenting capacity of B lymphocytes towards T lymphocytes (Defrance et al., 1994; Jeannin et al., 1997) . IL-4 and IL-13 upregulate the expression of anti-inflammatory cytokines of the IL-10 family in both macrophages and monocytes (Kambayashi et al., 1996; Gallagher et al., 2000) , but differentially regulate the release of proinflammatory cytokines by these two cell types (de Waal Malefyt et al., 1993; Hart et al., 1999) . IL-4, and to a lesser extent IL-13, are required for Th2 differentiation (Kopf et al., 1993; McKenzie et al., 1998) . Moreover, IL-4 and IL-13 act also on nonhematopoietic cells such as fibroblasts, endothelial cells and epithelial cells.
Biological activities of IL-4 and IL-13 are mediated through receptors composed of the IL-4Ra subunit associated either with the IL-2Rgc or with the IL-13Ra1 chains (Kondo et al., 1993; Russell et al., 1993; Aman et al., 1996; Miloux et al., 1997) . Indeed, the IL-4Ra/IL2Rgc receptor mediates IL-4 signaling specifically, whereas the IL-4Ra/IL-13Ra1 receptor, common to both IL-4 and IL-13, confers to these cytokines overlapping signaling pathways and biological activities.
In addition, another receptor chain has been described, the IL-13Ra2, which binds only IL-13 with high affinity, and not IL-4 (Caput et al., 1996) . IL-13Ra2 is unlikely to participate in the IL-4Ra/IL-2Rgc or IL-4Ra/IL-13Ra1 signaling receptors, and may function as a decoy receptor selective for IL-13, and not IL-4. Indeed, IL-13 binding to IL-13Ra2 transfected COS cells is not significantly modulated by the coexpression of IL-4Ra, IL-2Rgc or IL-13Ra1, and is not displaced by IL-4 (Caput et al., 1996) . It has otherwise been reported that binding of IL-13 to IL-13Ra2 induced a rapid internalization of the IL-13/IL-13Ra2 complex, and that IL-13Ra2 overexpression abrogated IL-13-induced STAT6 activation in CHO cells expressing IL-13Ra1 and IL-4Ra (Kawakami et al., 2001) . Thus, the level of IL-13Ra2 expression is likely to modulate the cell responsiveness to IL-13, without affecting IL-4 signaling.
IL-13Ra2 mRNA has been detected at low level in the myeloid TF-1 cells, the promonocytic U937 cells, the B-cell line IM9, the immature mast cell line HMC-1, the keratinocytic A431 and HaCaT cells, and in some but not all primary B lymphocytes and fibroblasts (Caput et al., 1996; Gauchat et al., 1997; Doucet et al., 1998; Feng et al., 1998; Ogata et al., 1998; David et al., 2001) . Interestingly, an abnormally high level of IL13Ra2 expression has been reported in glioblastomas, AIDS-Kaposi's sarcomas and cells derived from renal, colon, prostate and ovarian carcinomas (Caput et al., 1996; Maini et al., 1997; Murata et al., 1997; Debinski et al., 1999b; Husain and Puri, 2000) .
Little is known on the regulation of IL-13Ra2 mRNA expression, except in HaCaT cells in which we recently reported that IL-4 and IL-13 upregulate IL-13Ra2 expression at both the mRNA and protein levels (David et al., 2001) . Upregulation of IL-13Ra2 in response to IL-4 or IL-13 was shown to depend upon JAK2, ERK and p38 MAPK activation and to involve the transcription factor STAT6. Here we report that TNFa synergizes with either IL-4 or IL-13 in inducing IL-13Ra2 expression. To further investigate the mechanisms underlying this upregulation of IL-13Ra2 transcripts, we identified and cloned the promoter of the IL-13Ra2 gene and attempted to characterize IL-4/IL-13 and TNFa-responsive elements in this promoter sequence.
Results

TNFa synergizes with IL-4 or IL-13 in inducing IL-13Ra2 mRNA expression in HaCaT cells
We previously reported that IL-4 and IL-13 upregulate expression of the IL-13Ra2 chain in the HaCaT human keratinocytes cell line (David et al., 2001) . IL-4 and IL-13, when used at saturating concentrations, displayed neither additive nor synergistic effects, thus demonstrating a redundancy between the molecular mechanisms involved in IL-13Ra2 mRNA induction in response to either IL-4 or IL-13 (data not shown). To further investigate the regulation of IL-13Ra2 expression, we assessed the effects of some other cytokines on the level of IL-13Ra2 mRNA. We observed that TNFa potently synergizes with IL-4 or IL-13 in inducing IL-13Ra2 expression. Indeed, when IL-13Ra2 expression was assessed by RT-PCR in HaCaT cells, TNFa, which when used alone had no detectable effect, reproducibly induced an B10-fold increase over the IL-13Ra2 mRNA level induced by IL-4/IL-13 (Figure 1a ). Under the same conditions, however, levels of mRNA coding for the IL-4Ra and IL-13Ra1 chains, the other components of IL-4 and IL-13 receptors expressed in these cells, remained unaltered (Figure 1b) .
Whether an increased level of the IL-13Ra2 chain at the cell surface followed IL-13Ra2 mRNA induction was next studied by flow cytometry analysis using a specific monoclonal antibody ( Figure 1c) . Expression of IL-13Ra2 on untreated or TNFa-stimulated HaCaT cells was undetectable by this method. Indeed, histograms representative of the isotype control and untreated or TNFa-stimulated cells were superimposable. HaCaT cells were left untreated or stimulated for 8 h with IL-4, IL-13, TNFa or a combination of these cytokines. mRNA were prepared and used as template for RT-PCR using primers specific for exon 10 and exon 13 of the human IL-13Ra2 gene, or primers specific for IL-4Ra or IL-13Ra1. PCR products were run either on a 2% agarose gel, or on nondenaturing polyacrylamide gel stained with Vistra Green for quantification with a Storm FluorImager. Flow cytometry analysis of the expression of the IL-13Ra2 chain at the cell surface (c). HaCaT cells were left untreated (thin lines) or stimulated for 24 h with IL-4, IL-13, TNFa or combinations of these cytokines (thick lines, as indicated at the top of each histogram). Cells were then successively incubated with B-D13 antibody specific for the IL-13Ra2 chain, biotin goat anti-mouse IgG and Alexa Fluor 633 streptavidin conjugate. Fluorescence intensity (FI) was assessed by flow cytometry IL-4 or IL-13 alone induced a detectable expression of IL-13Ra2 chain. Consistent with the effect of TNFa on IL-4/IL-13-induced IL-13Ra2 mRNA expression, TNFa combined with IL-4 or IL-13 dramatically increased expression of IL-13Ra2 chain at the HaCaT cell surface.
We previously reported that upregulation of IL13Ra2 in response to IL-4 or IL-13 involves the transcription factor STAT6. Although IL-4 and IL-13 are the principal activators of STAT6, recent reports indicate that other stimuli can enhance IL-4/IL-13-induced STAT6 activation. In particular, CD40 provides a costimulatory signal for IL-4 by activating p38 MAPK, which increases the transactivation potential of STAT6 (Pesu et al., 2002) . This suggested that TNFa, which potently activates p38 MAPK, might also enhance IL-4/IL-13-induced STAT6 transcriptional activity. Moreover, TNFa has been described to induce directly a modest tyrosine phosphorylation of STAT6 in 3T3-L1 adipocytes (Guo et al., 1998) . Therefore, we investigated whether TNFa regulates STAT6 phosphorylation or transcriptional activity in HaCaT keratinocytes. As shown in Figure 2a , the level of tyrosine phosphorylation of STAT6 in HaCaT cells was not increased in response to TNFa, whether used alone or in combination with IL-4 or IL-13. Moreover, TNFa did not modulate the transcriptional activity of STAT6, as assessed by transient transfection experiments using a reporter construct whose transcription is under the control of five STAT6 responsive elements (Figure 2b ).
Thus, the synergistic effect of TNFa on IL-4/IL-13-induced IL-13Ra2 expression is unlikely to result from a direct regulation of STAT6 activity by TNFa-triggered signaling pathways.
Cloning of the 5
0 UTR of the IL-13Ra2 mRNA and genomic organization of the IL-13Ra2 gene
To investigate transcriptional mechanisms underlying the regulation of IL-13Ra2 expression, we then undertook to identify and to characterize the promoter sequences of IL-13Ra2 gene. We first sought to determine the transcription start site of the IL-13Ra2 gene by 5 0 RACE experiments. Owing to the technical limitation of 5 0 RACE experiments when applied to mRNA expressed at low level, only RNA prepared from HaCaT cells stimulated with both IL-4 and TNFa, which expressed the highest level of IL-13Ra2, were suitable for amplification of IL-13Ra2 5 0 UTR. Unfortunately, no 5 0 RACE experiment has been successfully performed with RNA prepared from untreated or IL-4/ IL-13-stimulated HaCaT cells. For 5 0 RACE experiments, the 5 0 ends of the full-length decapped mRNA were ligated to an RNA oligonucleotide adapter, and used as template for a random-primed reverse transcription. A nested PCR was then performed, using two forward primers complementary to sequence of the adapter and two reverse primers specific for the IL13Ra2 mRNA. Electrophoretic migration of the 5 0 RACE products displayed several discrete bands, suggesting the occurrence of multiple transcription start sites and/or alternative exon splicing. Cloning and nucleotide sequence analysis of 30 of these 5 0 RACE products revealed, indeed, the existence of three main species of IL-13Ra2 transcripts, differing in the length and sequence of their 5 0 UTR regions. Search for homologous sequences using BLAST software mapped the newly sequenced 5 0 UTR and the already published IL-13Ra2 partial cDNA sequences on the same human genomic sequence (Accession # AL121878) that became available during the course of this study. This sequence corresponds to the cytogenetic locus q24 of the X chromosome, consistent with the previously published chromosomal assignment of the IL-13Ra2 gene (Guo et al., 1997) . Gapped alignments of the 5 0 UTR and cDNA sequences on the AL121878 genomic DNA sequence indicate that IL-13Ra2 gene, spanning over approximately 38 kb, consists of four newly characterized 5 0 noncoding exons nine coding exons, and 12 introns ( Figure 3a ).
IL-13Ra2 mRNA initiate from multiple transcription initiation sites, and result from alternative exon splicing
Multiple sequence alignments of the cloned 5
0 RACE products demonstrated that the different IL-13Ra2 5 0 UTR resulted from alternative usage of the first four exons. As represented in Figure 3b , the longer 5 0 UTR cloned (corresponding to type I transcripts) contained these four exons, whereas shorter type II and type III alternative spliced transcripts lacked exon 2 or both 
Characterization and functional analysis of the P1 region
Analysis of the genomic sequences immediately upstream of the transcription start sites of IL-13Ra2, that is, the putative promoter region (which we named P1), failed to reveal consensus TATAA or CCAAT boxes. This observation is in accordance with numerous reports indicating that the transcription of mRNA that initiate from multiple sites are usually driven by TATA-less promoters (Ince and Scotto, 1995) . As shown in Figure 4 , analysis of the P1 promoter region for putative binding sites for transcription factors identified sites for STAT6, NFkB, C/EBPb and AP-1. Genomic DNA corresponding to the P1 region was amplified by PCR from the RP6-204F4 bacterial clone and introduced in the promoter-less luciferase reporter pGL3 Basic vector. This P1 promoter-driven luciferase construct (pGL3-P1) was transiently transfected in HaCaT cells and assayed for luciferase activity. As shown in Figure 5 , the P1 region displayed basal promoter activity, which was increased in response to either IL-4 or IL-13. This response to IL-4 or IL-13 was however not further increased by TNFa. Thus, our analysis of P1 promoter by transient transfection experiments suggested that despite the presence of a putative NFkB binding site, this region of the P1 promoter did not account for the synergistic effect of TNFa on IL-4/IL-13-induced IL-13Ra2 mRNA expression.
Implication of the (À139 to -130) STAT6 binding site of the P1 promoter in IL-4/IL-13-induced transcriptional regulation of IL-13Ra2 mRNA expression
We then focused on the elements that might account for IL-4/IL-13 regulation of P1. Both IL-4 and IL-13 are potent activators of STAT6 proteins, which preferentially recognize TTC(N) 4 GAA sites. We therefore sought to determine by electrophoretic mobility shift assay (EMSA) experiments whether the TTCAGGG-GAA and TTCCTCTGAA sequences that are present at positions (À1513 to À1504) and (À139 to À130) of the P1 promoter were indeed capable of binding STAT6 (Figure 6) . A gel mobility shift of 32 P-labeled synthetic probes corresponding to the (À1522 to À1492) and (À148 to À116) sequences of the P1 promoter was observed after incubation with nuclear extracts of IL-4-stimulated HaCaT cells, but not with extracts from unstimulated cells, demonstrating that an IL-4-activated protein bound to both probes. The presence of STAT6 in these DNA-protein complexes was demonstrated by supershift experiments using an antibody specific for STAT6. Competition by an excess of cold probe, but not by a random probe, demonstrated the specificity of this binding. In addition, a one-nucleotide insertion converting these TTC(N) 4 GAA sites to TTC(N) 5 GAA sequences completely abolished the binding of STAT6.
We then investigated the respective implication of the distal (À1513 to À1504) and of the proximal (À139 to À130) STAT6 binding sites in the IL-4/IL-13-induced P1 promoter activity, by generating several mutated or truncated constructs from the pGL3-P1 plasmid, as shown in Figure 7 . Mutation of both sites to the TTC(N) 5 GAA sequences, that was shown above to disrupt STAT6 binding, dramatically reduced the IL-4/ IL-13-induced luciferase activity, indicating that these sequences accounted for most of the IL-4/IL-13 response of this construct. Further analysis either by mutating each of these sites individually or by truncation removing the distal site showed that the proximal STAT6 response element was critical for this response. Moreover, cotransfection of an expression plasmid coding for STAT6VT, a partial gain-of-function mutant of STAT6, further increased the IL-4/IL-13-induced activity of promoter constructs containing the wild-type proximal STAT6 binding site, but not of the other pGL3-P1 constructs. This underlined the importance of the proximal STAT6 response element. Expression of STAT6VT in the absence of stimulation had no effect on promoter activity, in agreement with its previously described effect on IL-13Ra2 mRNA expression in HaCaT cells (David et al., 2001) . Taken together, these data demonstrate that whereas both STAT6 sites bind STAT6 efficiently in vitro, only the proximal site is required for the IL-4/IL-13-mediated increase of P1 promoter activity.
TNFa synergizes with IL-4 and IL-13 to regulate P1 promoter activity in the context of chromatin environment As described above, transient transfection of the pGL3-P1 construct did not reproduce the synergistic effect of TNFa on IL-4/IL-13-induced IL-13Ra2 mRNA expressions. Therefore, the possibility of a chromatin context requirement for the potentiation effect of TNFa on IL-4/IL-13-induced P1 promoter activity was investigated. Since transiently transfected DNA are aberrantly or not efficiently packaged into chromatin, we established HaCaT cells that harbor stably chromatin-integrated pGL3-P1 constructs containing either the wild-type or the mutated proximal STAT6 response element. In these stable cell populations, IL-4 and IL-13 effects on P1 promoter activity were quite similar to those obtained in transient transfection experiments. Indeed, IL-4/IL-13 ability to enhance P1 promoter activity was dependent upon integrity of the proximal STAT6 binding site (Figure 8 ). Interestingly, in contrast to results obtained in transient transfection experiments, TNFa efficiently potentiated IL-4/IL-13-induced P1 promoter activity in stable transfectants, thus mimicking endogenous IL13Ra2 gene regulation. The inducibility of P1 promoter activity by combinations of TNFa with either IL-4 or IL-13 was nearly abrogated by mutation of the proximal STAT6 binding site.
Taken together, these results suggest that at least one TNFa-responsive element is present in the (À1529 to Figure 5 Analysis of promoter activity of the P1 region. The (À1529 to +88) region of P1 was cloned in the pGL3 Basic vector (pGL3-P1) and cotransfected with the pCMV b-galactosidase plasmid in HaCaT cells. At 12 h after transfection, cells were stimulated for 36 h with the indicated cytokines or left unstimulated (NS). Luciferase activity was normalized for b-galactosidase activity Figure 6 The (À1513 to À1504) and (À139 to À130) elements of the P1 promoter bind STAT6 in vitro. Radiolabeled probes corresponding to the (À1522 to À1492) and (À148 to À116) sequences of the P1 region were incubated with nuclear extracts of untreated or IL-4-stimulated HaCaT cells, and analysed for gel mobility shift. In parallel, probes mutated such as the TTC(N) 4 GAA potential STAT6 binding sites converted to TTC(N) 5 GAA (mut) were used. An anti-STAT6 antibody (AB) was used in supershift experiments, and the specificity of the DNAprotein complexes was assessed using excess of random (Rd) or cold probes +88) P1 promoter region. Consistent with TNFa inability to regulate IL-13Ra2 mRNA expression, binding of this element by a TNFa-activated transacting factor, yet to be identified, is not sufficient to induce transcription from P1 promoter. The differential regulation of extrachromosomal and integrated pGL3-P1 reporter constructs by TNFa suggests the involvement of chromatin-specific regulatory mechanisms of the P1 locus in response to TNFa.
Discussion
Overexpression of the IL-13Ra2 chain has been reported in various human tumor cells, derived from high-grade gliomas, AIDS-Kaposi's sarcomas and renal, colon, prostate or ovarian carcinomas (Caput et al., 1996; Maini et al., 1997; Murata et al., 1997; Debinski et al., 1999b; Husain and Puri, 2000) . This receptor chain has thus been proposed to represent a novel target for therapy. Indeed, a chimeric protein composed of IL-13 and Pseudomonas exotoxin was reported to be highly cytotoxic to these carcinoma cells (Debinski et al., 1995; Maini et al., 1997; Debinski et al., 1999a) . Furthermore, a soluble recombinant IL-13Ra2 protein has been constructed, which efficiently inhibits IL-13 activity in mouse models of Th2 cell-mediated reactions induced by Schistosoma mansoni eggs and of allergic lung diseases (Grunig et al., 1998; Wills-Karp et al., 1998; Chiaramonte et al., 1999) . Even though the physiologic role of IL-13Ra2 chain needs to be further characterized, IL-13Ra2 is presumed to downregulate the cell responsiveness to IL-13, suggesting that the expression of IL13Ra2 should be tightly regulated. Indeed, we previously reported that in HaCaT cells IL-4 and IL-13 upregulated IL-13Ra2 at both the mRNA and protein levels (David et al., 2001) . IL-13Ra2 expression can be also increased by post-translational mechanisms: membrane expression of IL-13Ra2 in monocytes is upregulated in response to IFNg, by mobilization of preformed IL-13Ra2 protein from intracellular compartment to the cell surface (Daines and Hershey, 2002) .
In this work, we focused on the transcriptional regulation of IL-13Ra2 expression, and therefore undertook experiments aimed at identifying the promoter sequence of the IL-13Ra2 gene. We cloned the 5 0 UTR of IL-13Ra2 transcripts and describe here the genomic organization of the IL-13Ra2 locus. The IL-13Ra2 gene spans over approximately 38 kb, and consists of at least 13 exons and 12 introns. 5
0 RACE experiments performed in this study demonstrated the existence of alternative spliced IL-13Ra2 transcripts in HaCaT cells stimulated with IL-4 and TNFa. Unfortunately, the possibility of a differential expression of these alternative transcripts in HaCaT cells stimulated with different combination of TNFa, IL-13 and IL-4, or left Figure 7 The (À139 to À130) STAT6 site of the P1 promoter mediates the IL-4/IL-13-induced P1 promoter activity. Various truncated or mutated plasmids were generated from the pGL3-P1 construct, as shown in the left panel. HaCaT cells were transfected with these constructs as in Figure 5 and assayed for luciferase activity (center panel). The various luciferase reporter constructs were also cotransfected with the STAT6VT expression plasmid, and stimulated for 20 h with IL-4 or IL-13 (right panel). Luciferase activity was normalized for b-galactosidase activity. The results are expressed as the folds increase in relative light units in response to the IL-4/ IL-13 stimulation Figure 8 TNFa increases promoter activity of chromatin-integrated pGL3-P1 construct. HaCaT cells were stably transfected with pGL3-P1 constructs containing either the wild-type or the mutated STAT6 proximal binding site (pGL3-P1 prox mut). After being selected, cells were stimulated with IL-4, IL-13, TNFa or combinations of these cytokines and assayed for luciferase activity. The results are expressed as the folds increase in relative light units in response to stimulations Transcriptional regulation of IL-13Ra2 expression MD David et al untreated, could not been investigated, because of the technical limitation of 5 0 RACE experiments when applied to mRNA expressed at low level. Alternative splicing occurring in the 5 0 UTR of various genes has been reported to affect translation efficiency or mRNA stability, and to regulate splicing at further 3 0 sites (Chen et al., 1998; van der Velden and Thomas, 1999) . In particular, alternative splicing of transcripts coding for many members of the hematopoietin receptor family accounts for the expression of soluble forms of receptor chains. Interestingly, the existence of such a soluble form of IL-13Ra2 chain has been described in serum and urine of mice (Zhang et al., 1997) . As demonstrated by flow cytometry experiments, at least one of the three alternative IL-13Ra2 transcripts expressed in HaCaT cells stimulated with IL-4 and TNFa is efficiently translated and encodes for the membrane form of the IL-13Ra2 chain. The significance of the alternative splicing occurring in the IL-13Ra2 5 0 UTR with regard to the final protein product(s) therefore remains to be addressed.
It may be of interest that, in addition to the major species of mRNA starting at exon 1, a few mRNAs identified by 5 0 RACE experiments appeared to initiate from exon 2 (data not shown), suggesting the existence of an alternative promoter. The activity of this putative P2 promoter could, however, not be confirmed by conventional methods. Whether this or other alternative promoters could be used at a higher frequency in other cell types remains to be investigated.
The promoter activity of the genomic region upstream exon 1 was assessed in HaCaT cells. The (À1529 to +88) region of the P1 promoter efficiently drove transcription when inserted in the pGL3 luciferase reporter vector. In both transient and stable transfection experiments, promoter activity of this pGL3-P1 construct was significantly increased in response to IL-4 and IL-13. Moreover, a STAT6 binding site located in the proximal region of the P1 promoter was shown to be critical for IL-4/IL-13-induced P1 promoter activity. This is in agreement with our previous report that demonstrated the ability of IL-4 and IL-13 to regulate IL-13Ra2 mRNA expression (David et al., 2001) , and provides further understanding concerning the involvement of STAT6 in this process. At last, TNFa was shown to potentiate IL-4/IL-13-induced P1 promoter activity, when studied in stable but not in transient transfection, suggesting the occurrence, in response to TNFa, of chromatin remodeling at the P1 promoter site. Consistent with this hypothesis, involvement of cofactor-dependent histone acetyltransferase activity for transcriptional activation by NFkB has been evidenced. Indeed, interaction between NFkB and coactivators such as CBP, p300, p/CAF and SRC-1 potentiates NFkB-driven gene expression (Na et al., 1998; Sheppard et al., 1999; Vanden Berghe et al., 1999) .
Taken together, these data indicate that the P1 promoter accounts at least partially for the regulation of IL-13Ra2 mRNA expression in HaCaT cells stimulated with combinations of IL-4, IL-13 and TNFa. However, the extent of regulation of the pGL3-P1 promoter activity appeared relatively low as compared to the induction level of IL-13Ra2 mRNA in response to these cytokines. Thus, it cannot be ruled out that distal enhancer elements not identified thus far may participate in the regulation of the P1 promoter activity. Alternatively, IL-13Ra2 mRNA expression could be also regulated at post-transcriptional level, by mRNA stabilization.
Although the precise function(s) of IL-13Ra2 is still poorly understood, it is not questionable that regulation of its expression play an important role in modulating the cell responsiveness to IL-13. It is currently accepted that IL-13Ra2 expression may downregulate cell responsiveness to IL-13, by either its decoy effect or by increasing internalization of the cytokine/receptor complex. In this regard, it is of interest that IL-13 regulates IL-13Ra2, thus leading to a regulatory feedback loop. The identification and characterization of the promoter sequence of IL-13Ra2 gene reported here may help in understanding how its expression is regulated under physiological circumstances or dysregulated in a number of tumor cells.
Materials and methods
Flow cytometry analysis
The human keratinocyte cell line HaCaT (Boukamp et al., 1988 ) was cultured as previously described (David et al., 2001) . For flow cytometry analysis, HaCaT cells were stimulated for 24 h with 10 ng/ml IL-4 or IL-13, alone or in combination with 5 ng/ml TNFa (TEBU, Rocky Hill, NJ, USA) or left untreated. Cells were harvested and incubated successively at 41C for 20 min with the B-D13 anti-IL-13Ra2 monoclonal antibody (Diaclone, France) or an isotype control, for 15 min with biotin goat anti-mouse IgG (Molecular Probe, Eugene, OR, USA), and then for 15 min with Alexa Fluor 633 streptavidin conjugate (Molecular Probe, Eugene, OR, USA). Fluorescence was measured using a FACSCalibur.
Immunoprecipitation and Western blotting
HaCaT cells were stimulated with combinations of TNFa, IL-4 or IL-13, as indicated, and lysed as previously described (Wery-Zennaro et al., 1999) . Cell lysates (1 mg) were incubated with rabbit anti-STAT6 (S-20) antibody from Santa-Cruz (Santa Cruz, CA, USA) and protein A-Sepharose beads at 41C. The immunoprecipitates were separated through 8% SDS-PAGE. Proteins were transferred to Hybond-C extra membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). Membrane was hybridized with appropriate antibodies. The blots were developed by using enhanced chemiluminescence assay (Amersham Pharmacia Biotech, Uppsala, Sweden).
Rapid amplification of cDNA ends (5 0 RACE)
The 5 0 ends of the IL-13Ra2 mRNA were investigated using the FirstChoicet RLM-RACE Kit (Ambion, Woodward Austin, TX, USA), as described by the manufacturer. For nested PCR amplifications, the IL-13Ra2-specific reverse primers were CTCGGTGTCTGAAGATGAAG (outer primer) and gcatgtcgacTGACCAGGTTATGGCGACTT (inner primer), corresponding to (+87 to +68 nt) and (À58 to À77 nt) relative to the translation initiation codon on the published IL-13Ra2 cDNA sequence (Accession # Y08768). Nested PCR amplifications were performed using 0.5 mm of each primer, 200 mm of each dNTP, 1.2 mm of Mg(OAc) 2 and 1 U of rTth Polymerase XL (Applied Biosystems, Foster City, CA, USA), and were carried out during 35 cycles of successive incubations at 941C (30 s), at 651C (30 s) and at 701C (1 min). PCR products were either run on a 2% agarose gel or cloned in the pGEM-3Z plasmid (Promega, Madison, WI, USA) and sequenced.
RT-PCR
Total RNA extraction, reverse transcription and PCR amplifications displayed in Figure 1 were performed as previously described (Wery-Zennaro et al., 1999) .
EMSAs
HaCaT cells were stimulated with IL-4 during 40 min, scrapped in PBS supplemented with 1 mm Na 3 VO 4 , and pelleted. Nuclear extracts, radiolabeled double-strand oligonucleotides were prepared and EMSA experiments performed as previously described (Wery-Zennaro et al., 2000) . The oligonucleotides used were GCTAGAGGATTCAGGG-GAAACAGGAAGCTTG (À1522 to À1492 nt) of P1, containing the distal STAT6 binding site), CTTTGTAAT-TTCCTCTGAATCTTTTGACAAATG (À148 to À116 nt) of P1, containing the proximal STAT6 binding site), and two oligonucleotides containing one nucleotide insertion in the STAT6 binding sites: GCTAGAGGATTCAGGGTGAA-ACAGGAAGCTTG and CTTTGTAATTTCCTCTTGAA-TCTTTTGACAAATG, respectively. Supershift experiments were performed using the anti-STAT6 (S-20) antibody from SantaCruz (Santa Cruz, CA, USA).
Plasmid constructs
Human genomic DNA was purified from the bacterial clone RP6-204F4 (Invitrogen, Carlsbad, CA, USA), and used as template for PCR reactions. The 5 0 truncated P1 promoter fragments (shown in Figure 7) were amplified using the following primers: ccgctcgagTGCAGGAGCTAGAGGATT-CA (forward primer for pGL3-P1 construct), ccgctcgag-GAGGGAAAGCCTAGAGTAGA (forward primer for pGL3-P1d construct), ccgctcgagAACCTTAAATGCTGACC-TA (forward primer for pGL3-P1D construct) and gtcaccgcggAACAATGTGTCCAGTTGTAA (reverse primer for all pGL3-P1 constructs). The PCR amplified promoter fragments were digested by XhoI and inserted in the XhoI/HindIII-blunt ended pGL3 Basic vector. Mutations in the STAT6 binding sites of the pGL3-P1 construct were performed with the QuickChange site directed mutagenesis kit (Stratagen, La Jolla, CA, USA) and the primers used in EMSA experiments. The STAT6VT expression plasmid was previously described (David et al., 2001) .
Transfection, luciferase and b-galactosidase assays
Exponentially growing HaCaT cells were trypsinized, washed and resuspended in 700 ml of an optimized electroporation medium (David et al., 2001) . For transient transfection experiments, 3 Â 10 7 cells were incubated with 20 mg of luciferase reporter plasmid and 2 mg of pCMV b-galactosidase plasmid (Clontech, Palo Alto, CA, USA). In cotransfection experiments, 10 mg of pCMV-Tag-STAT6VT or empty plasmids were added. Cells were pulsed at 320 V and 960 mF and plated in 10% FCS-containing DMEM. After 12 h, cells were either left untreated or stimulated with IL-4, IL-13 and/or TNFa in a serum-free DMEM for the indicated times. Cells were lysed in Reporter Lysis Buffer (Promega, Madison, WI, USA) and luciferase and b-galactosidase activities of lysates were quantified as described by the manufacturer. Results are the mean of four experiments performed in triplicates. For stable transfection experiments, HaCaT cells were cotransfected with luciferase reporter constructs and a plasmid containing the neomycin phosphotransferase gene, and then cultured under 500 mg/ml G418 selective conditions during 1 month. Resistant cells were pooled for further experiments, in order to avoid individual clonal variation, thus providing a reliable response upon cytokine treatments.
